Clinical trial
Development and Evaluation of an AI Agent-Assisted Proactive Postdischarge Management Model for Patients With Decompensated Cirrhosis
NCT07931404 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, 180 participants (estimated). Lead sponsor Beijing Tsinghua Chang Gung Hospital; China. Primary measure: Proportion of Participants With a First Liver-Related Unplanned Acute Healthcare Utilization Event Within...
Registry record
As filed in ClinicalTrials.gov.
- Title
- Development and Evaluation of an AI Agent-Assisted Proactive Postdischarge Management Model for Patients With Decompensated Cirrhosis
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- February 29, 2028
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them.
decompensated liver cirrhosis
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| AI Agent-Assisted Proactive Management Plus Standard Care | Experimental | AI Agent-Assisted Proactive Management, Standard Care |
Show registry wordingParticipants will receive standard care plus 90 days of AI agent-assisted proactive management after discharge. Participants or authorized caregivers will submit brief daily health reports and may report symptoms as they occur. The service combines AI-supported information structuring, rules-based risk alerts, nurse verification, physician-led clinical decisions, and documentation of actions and follow-up. | ||
| Standard Care | Active comparator | Standard Care |
Show registry wordingParticipants will receive standard care without access to the study AI agent-assisted proactive management service. Existing outpatient care, telephone follow-up, clinical contact channels, and access to emergency care will be maintained. Scheduled study outcome ascertainment and safety follow-up will be performed at the same frequency as in the experimental group. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Proportion of Participants With a First Liver-Related Unplanned Acute Healthcare Utilization Event Within 90 Days | From discharge following the index hospitalization (Day 0) through Day 90. |
Show registry wordingProportion of participants with at least one unplanned emergency department visit, hospital observation stay, acute day-case treatment, or readmission due to acute deterioration of liver disease within 90 days after index-hospital discharge. Contacts arising from the same episode of deterioration count as one composite event. Planned care without acute deterioration and routine consultations do not qualify. Events will be verified from hospital records, authorized external records, and identical follow-up schedules in both groups. Two independent adjudicators blinded to group assignment will review events; a third will resolve disagreements. Death and liver transplantation before a qualifying event will be recorded as competing events. Uncertain event status will not be classified as no event. | |
Lead sponsor's other trials
Beijing Tsinghua Chang Gung Hospital, most recent start first.
+104 more trials See the organization page